218 related articles for article (PubMed ID: 15842347)
1. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
Martinowitz U; Michaelson M;
J Thromb Haemost; 2005 Apr; 3(4):640-8. PubMed ID: 15842347
[TBL] [Abstract][Full Text] [Related]
2. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
[TBL] [Abstract][Full Text] [Related]
3. Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
Martinowitz U; Kenet G; Segal E; Luboshitz J; Lubetsky A; Ingerslev J; Lynn M
J Trauma; 2001 Sep; 51(3):431-8; discussion 438-9. PubMed ID: 11535886
[TBL] [Abstract][Full Text] [Related]
4. When all else fails to stop massive bleeding from trauma.
Thompson AR
J Thromb Haemost; 2005 Apr; 3(4):638-9. PubMed ID: 15842346
[No Abstract] [Full Text] [Related]
5. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
6. Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig.
Sapsford W; Watts S; Cooper G; Kirkman E
J Trauma; 2007 Apr; 62(4):868-79. PubMed ID: 17426541
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
[TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
9. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
[TBL] [Abstract][Full Text] [Related]
10. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.
Vincent JL; Rossaint R; Riou B; Ozier Y; Zideman D; Spahn DR
Crit Care; 2006; 10(4):R120. PubMed ID: 16919168
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
Hoots WK
Hematology Am Soc Hematol Educ Program; 2006; ():426-31. PubMed ID: 17124094
[TBL] [Abstract][Full Text] [Related]
12. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
[TBL] [Abstract][Full Text] [Related]
13. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
Pychyńska-Pokorska M; Moll JJ; Krajewski W; Jarosik P
Pediatr Crit Care Med; 2004 May; 5(3):246-50. PubMed ID: 15115562
[TBL] [Abstract][Full Text] [Related]
14. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.
Martinowitz U; Holcomb JB; Pusateri AE; Stein M; Onaca N; Freidman M; Macaitis JM; Castel D; Hedner U; Hess JR
J Trauma; 2001 Apr; 50(4):721-9. PubMed ID: 11303171
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa in the treatment of bleeding.
Midathada MV; Mehta P; Waner M; Fink LM
Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
[TBL] [Abstract][Full Text] [Related]
16. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage.
Bowles KM; Callaghan CJ; Taylor AL; Harris RJ; Pettigrew GJ; Baglin TP; Park GR
Br J Anaesth; 2006 Oct; 97(4):476-81. PubMed ID: 16914465
[TBL] [Abstract][Full Text] [Related]
17. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.
Mohr AM; Holcomb JB; Dutton RP; Duranteau J
Crit Care; 2005; 9 Suppl 5(Suppl 5):S37-42. PubMed ID: 16221318
[TBL] [Abstract][Full Text] [Related]
18. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
19. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
Murkin JM
Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
[TBL] [Abstract][Full Text] [Related]
20. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.
Gerotziafas GT; Zervas K; Arzoglou P; Karavaggeli E; Parashou S; Van Dreden P; Christakis J; Samama MM
Br J Haematol; 2002 Jun; 117(3):705-8. PubMed ID: 12028045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
